Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Operating Leases (2019 - 2025)

Medifast's Operating Leases history spans 7 years, with the latest figure at $10.7 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 7.55% year-over-year to $10.7 million; the TTM value through Dec 2025 reached $10.7 million, up 7.55%, while the annual FY2025 figure was $10.7 million, 7.55% up from the prior year.
  • Operating Leases reached $10.7 million in Q4 2025 per MED's latest filing, up from $6.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $31.0 million in Q1 2022 to a low of $6.6 million in Q1 2021.
  • Average Operating Leases over 5 years is $17.3 million, with a median of $15.8 million recorded in 2021.
  • Peak YoY movement for Operating Leases: skyrocketed 370.12% in 2022, then plummeted 62.6% in 2025.
  • A 5-year view of Operating Leases shows it stood at $26.0 million in 2021, then dropped by 22.08% to $20.3 million in 2022, then fell by 20.46% to $16.1 million in 2023, then tumbled by 38.35% to $9.9 million in 2024, then grew by 7.55% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for MED's Operating Leases are $10.7 million (Q4 2025), $6.8 million (Q3 2025), and $7.1 million (Q2 2025).